Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
This formulation provides a balanced mixture of amino acids, dextrose, electrolytes, and calcium for parenteral nutrition. Amino acids serve as substrates for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; calcium is essential for bone mineralization and neuromuscular function.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Provision of calories, amino acids, electrolytes, and calcium in a single container
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
Dose is patient-specific based on caloric and electrolyte needs. Typical adult: 500-3000 m L intravenously over 24 hours; contains 25% dextrose (250 g/L) and 5% amino acids. Infuse via central line due to high osmolarity.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Variable; amino acids have half-lives of minutes to hours; dextrose is rapidly cleared (half-life < 30 min). No terminal elimination half-life defined for mixture.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Amino acids undergo hepatic deamination and transamination; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are regulated by renal and gastrointestinal mechanisms; calcium is distributed in bone and soft tissues.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Renal: amino acids and dextrose metabolites are excreted renally; calcium and electrolytes are also cleared renally. Biliary/fecal: negligible.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Amino acids: minimal (10-20%); calcium: ~40% bound to albumin; dextrose: not bound.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Amino acids: 0.5-1.0 L/kg (total body water); calcium: 0.2-0.3 L/kg; dextrose: 0.2 L/kg (extracellular fluid).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intravenous: 100%.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
Contraindicated or dose-reduce in severe renal impairment (GFR <30 m L/min) due to risk of fluid overload and electrolyte imbalances. Monitor potassium, phosphorus, and magnesium closely.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Use with caution in severe hepatic impairment (Child-Pugh class C). May worsen hepatic encephalopathy due to amino acid load; consider specialized formulations.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Dose individualized; typical infusion rate: 0.5-8 mg/kg/min dextrose equivalent. Calculate based on weight (kg), fluid requirements, and nutritional goals. Avoid in neonates with hyperbilirubinemia.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Start at low end of dose range, monitor for fluid overload and electrolyte disturbances due to decreased renal function and comorbidities. Use cautious infusion rates.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not for use in patients with known hypersensitivity to any component. Contains aluminum that may be toxic with prolonged administration in renal impairment.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Risk of hyperglycemia, fluid overload, electrolyte disturbances, and aluminum toxicity,Monitor serum glucose, electrolytes, liver function, and acid-base status regularly,Use with caution in hepatic or renal impairment, heart failure, and hypercalcemia,Do not administer simultaneously with blood through same tubing
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Hypersensitivity to any component,Severe electrolyte disorders (e.g., hyperkalemia, hypercalcemia),Severe hepatic or renal impairment,Anuria, oliguria, or dialysis dependency
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
No direct food interactions as this product is administered intravenously. However, patients receiving parenteral nutrition should not eat or drink unless approved by the dietitian or doctor to avoid aspiration or metabolic imbalances. Enteral intake may affect blood glucose and electrolyte levels.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
CLINIMIX E 5/25 contains dextrose, amino acids, electrolytes, and calcium. Dextrose at high concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsulinemia and neonatal hypoglycemia, but no direct teratogenicity in first trimester. No specific teratogenic risks from amino acids or electrolytes at therapeutic doses. Calcium administration may affect fetal calcium homeostasis if maternal levels are markedly elevated. Overall, risk is related to underlying maternal condition rather than direct drug effect.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
CLINIMIX E 5/25 components are endogenous substances normally present in breast milk. Dextrose and amino acids infused are metabolized and do not accumulate in milk at significant levels. Electrolytes and calcium are tightly regulated. No M/P ratio available. Use is considered compatible with breastfeeding when clinically indicated.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pregnancy does not typically require dose adjustments for CLINIMIX E 5/25. However, adjustments may be needed for underlying metabolic conditions (e.g., gestational diabetes) or to avoid hyperglycemia. Calcium content should be monitored to avoid hypercalcemia. Individualize based on maternal glucose and electrolyte levels.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
This product is a dual-chamber bag containing amino acids 5%, dextrose 25%, and electrolytes including calcium. The 'Sulfite Free' designation is critical for patients with sulfite sensitivity. Calcium-containing PN must not be co-administered with ceftriaxone due to precipitation risk. Inline filter of 1.2 micron is recommended. Monitor serum calcium, phosphorus, and magnesium closely when adjusting PN. Hepatic function and triglycerides should be assessed if used for long-term nutrition.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This medication provides complete nutrition through your vein; it is not for oral use.,You may need blood tests to monitor your sugar, electrolyte levels, and liver function.,Report any signs of infection (redness, swelling, pain) at the IV site immediately.,Do not stop or change the infusion rate without consulting your doctor.,Tell your healthcare provider about any allergies, especially to sulfites.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by This formulation provides a balanced mixture of amino acids, dextrose, electrolytes, and calcium for parenteral nutrition. Amino acids serve as substrates for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; calcium is essential for bone mineralization and neuromuscular function.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Dose is patient-specific based on caloric and electrolyte needs. Typical adult: 500-3000 m L intravenously over 24 hours; contains 25% dextrose (250 g/L) and 5% amino acids. Infuse via central line due to high osmolarity.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 5/25 contains dextrose, amino acids, electrolytes, and calcium. Dextrose at high concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsul. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.